
    
      A cross-sectional study was performed in non-obese premenopausal women with prolactinoma
      treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model
      Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist
      circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG).
      They were compared with control women of similar age and BMI distribution.
    
  